Company research
OS Therapies Inc
CIK 1795091Updated Oct 6, 2026
SecurityOSTX · NYSE_AMERICAN · equity
OSTX price & chart
Loading TradingView…
AMEX:OSTX on TradingView ↗About the company
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD, and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX) News provided by Purcell & Lefkowitz LLP Jan 05, 2026, 08:10 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcel ↗
Seeking Alpha
Guardant Health CMO resigns ↗
Recent filings
3 filing
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 1.01, 5.02, 8.01, 9.01
S-8 filing
Other Events
Items 8.01, 9.01
424B7 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 6,839,534Source | 5,538,797Source | 798,082Source |
| Property, Plant and Equipment, NetUSD | 2,490Source | 5,270Source | 8,050Source |
| Current assets: | |||
| Assets, CurrentUSD | 332,912Source | 5,533,527Source | 790,032Source |
| Prepaid Expense and Other Assets, CurrentUSD | 63,082Source | — | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 11,864,460Source | 4,727,310Source | 24,814,297Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | — | — | 1,302Source |
| Common Stock, Value, IssuedUSD | 37,116Source | 20,870Source | 5,340Source |
| Additional Paid in CapitalUSD | — | 35,144,967Source | 5,495,330Source |
| Retained Earnings (Accumulated Deficit)USD | -67,186,219Source | -40,404,350Source | -29,518,187Source |
| Stockholders' Equity Attributable to ParentUSD | -6,095,631Source | -5,238,513Source | -24,016,215Source |
| Additional Paid in Capital, Common StockUSD | 61,053,472Source | — | — |
| Liabilities and EquityUSD | 6,839,534Source | 5,538,797Source | 798,082Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 11,764,460Source | 4,627,310Source | 24,714,297Source |
| Accounts Payable, CurrentUSD | 9,936,387Source | 1,662,068Source | 2,715,399Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 1,415,002Source | 521,010Source | 162,500Source |
| Dividends Payable, CurrentUSD | 375,000Source | 375,000Source | 343,750Source |
| Dividends PayableUSD | 375,000Source | 375,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,265,957Source | 268,300Source | — |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 8,274,316Source | -1,053,331Source | 1,347,602Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -14,238,576Source | -7,282,295Source | -3,006,967Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -466,423Source | — | 1,145Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,441,302Source | 12,776,840Source | 2,873,324Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 269,830Source | 5,533,527Source | 38,982Source |
| Additional Financial Items | |||
| AmortizationUSD | 360,305Source | — | — |
| Share-based Payment Arrangement, ExpenseUSD | 4,265,374Source | 268,300Source | 0Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 1,425,679Source | 2,646,459Source |
| DepreciationUSD | — | 2,780Source | 4,220Source |
| Dividends Payable, CurrentUSD | 375,000Source | 375,000Source | 343,750Source |
| Dividends PayableUSD | 375,000Source | 375,000Source | — |
| General and Administrative ExpenseUSD | 12,344,976Source | 3,974,786Source | 1,125,712Source |
| InterestExpenseNonoperatingUSD | — | 2,051,839Source | 3,448,939Source |
| Investment Income, InterestUSD | 249Source | — | 2Source |
| Net Income (Loss) Attributable to ParentUSD | -28,753,844Source | -8,882,938Source | -7,791,582Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -28,753,844Source | -10,886,163Source | -7,916,582Source |
| Nonoperating Income (Expense)USD | -48,143Source | -2,069,092Source | -3,448,937Source |
| Other Interest and Dividend IncomeUSD | — | 1,971,975Source | — |
| Proceeds from Issuance of Redeemable Preferred StockUSD | — | 6,050,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -28,705,701Source | -6,813,846Source | -4,342,645Source |
| Net Income (Loss) Attributable to ParentUSD | -28,753,844Source | -8,882,938Source | -7,791,582Source |
| Earnings Per Share, BasicUSD per share | -0.98Source | -0.88Source | -1.46Source |
| Earnings Per Share, DilutedUSD per share | -0.98Source | -0.88Source | -1.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 12,377,299Source | 5,429,248Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 29,253,292Source | — | — |
| Interest Expense (non-operating)USD | — | 2,051,839Source | 3,448,939Source |
| Additional Financial Items | |||
| Depreciation, Depletion and Amortization, NonproductionUSD | 363,085Source | — | — |
| General and Administrative ExpenseUSD | 12,344,976Source | 3,974,786Source | 1,125,712Source |
| Investment Income, InterestUSD | 249Source | — | 2Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -28,753,844Source | -10,886,163Source | -7,916,582Source |
| Nonoperating Income (Expense)USD | -48,143Source | -2,069,092Source | -3,448,937Source |
| Other ExpensesUSD | — | 714,943Source | 444,421Source |
| Other Interest and Dividend IncomeUSD | — | 1,971,975Source | — |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | 31,250Source | 125,000Source |
| Research and Development ExpenseUSD | 16,360,725Source | 2,839,060Source | 3,216,933Source |
Filing attachments
ea030761101ex99-1.htm · 8-K · 2026-10-05
Exhibit 99.1 October 1, 2026 ─────────────────── OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company’s lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac) Grasonville, Maryland--(Newsfile Corp. - October 1, 2026) - OS Therapies, Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader…
Read attachment ↗ea030148501ex4-1.htm · 8-K · 2026-08-12
EX-4.1 3 ea030148501ex4-1.htm FORM OF SENIOR SECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THIS NOTE HAS BEEN ISSUED WITH “ORIGINAL ISSUE DISCOUNT” FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUER WILL MAKE AVAILABLE TO ANY HOLDER OF THIS NOTE: (1) THE ISSUE PRICE AND ISSUE DATE OF THE NOTE, (2) THE AMOUNT OF ORIGINAL ISSUE DISCOUNT ON THE NOTE, (3) THE YIELD TO MATURITY OF THE NOTE, AND (4) ANY OTHER INFORMATION REQUIRED TO BE MADE AVAILABLE BY U.S. TREASURY REGULATIONS UPON RECEIVING A …
Read attachment ↗ea030148501ex4-2.htm · 8-K · 2026-08-12
EX-4.2 4 ea030148501ex4-2.htm FORM OF COMMON STOCK PURCHASE WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE S…
Read attachment ↗ea030148501ex4-3.htm · 8-K · 2026-08-12
EX-4.3 5 ea030148501ex4-3.htm FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT …
Read attachment ↗ea030148501ex4-4.htm · 8-K · 2026-08-12
EX-4.4 6 ea030148501ex4-4.htm FORM OF PLACEMENT AGENT WARRANT Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURIT…
Read attachment ↗ea030084801ex4-1.htm · 8-K · 2026-08-06
EX-4.1 2 ea030084801ex4-1.htm FORM OF BRIDGE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 BRIDGE CONVERTIBLE PROMISSORY NOTE Purchase Price: $2,190,000 Principal Amount: $2,200,000 Date of Issuance: August 2, 2026 FOR VALUE RECEIVED, OS Therapies Incorporated, a Delaware corporation (the “Company”), hereby promises to pay to _________ (the “Holder”), the principal sum of $2,200,000 (the “Principal Amount”). Non-Interest Bearing. This Note shall be non-interest bearing, and no interest shal…
Read attachment ↗